Abstract 4395
Background
In BMA117159, GSK2857916, a humanised (IgG1), afucosylated, anti-BCMA monoclonal antibody conjugated to monomethyl auristatin-F, has shown clinical activity (overall response rate [ORR]=60%; mPFS 12 months [95% CI, 3.1–NE]) as monotherapy in heavily pre-treated patients with MM. Pre-clinical data indicate that GSK’916 induces immunogenic cell death that activates dendritic cells and an antigen-specific T-cell response. PD-L1 overexpression may be a mechanism of immune evasion in MM. Pembrolizumab, a selective, humanised IgG4 anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 with PD-L1 and PD-L2, may synergise with immunomodulatory drugs to enhance tumor suppression. T-cell-dependent antitumor response induced by GSK’916 may be augmented by combining with pembrolizumab.
Trial design
DREAMM 4 is a Phase I/II, single-arm, open-label, two-part study to evaluate safety and determine the recommended Phase 2 dose (RP2D) and clinical activity of GSK’916 in combination with pembrolizumab in patients with RRMM previously treated with ≥3 prior lines. Part 1 (dose escalation) will evaluate two doses of GSK’916 with a fixed dose of pembrolizumab in up to 12 participants. Modified Toxicity Probability Interval design will guide GSK’916 dose escalation. Primary objectives of Part 1 are to define safety and tolerability and define the RP2D dose of GSK’916 combined with pembrolizumab. Part 2 (dose expansion) will evaluate clinical activity of the RP2D, confirm safety, and collect pharmacokinetic information for GSK’916 in up to 28 participants. Dose expansion may stop early for futility at interim analysis. An additional stopping rule may stop enrolment early if the observed rate of treatment-related ≥Grade 4 AEs equals or exceeds the specified rate (12%). Part 2 objectives are to assess the ORR and confirm the safety profile of GSK’916 and pembrolizumab. Patients will continue combination treatment for 35 cycles or until progression, intolerance, consent withdrawal or death. Enrolment began in March 2019 and is ongoing.
Clinical trial identification
NCT03848845 (Rel. 19Feb2019).
Editorial acknowledgement
Clare Slater, PhD, of Fishawack Indicia Ltd, UK, funded by GlaxoSmithKline (GSK).
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline and is in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.
Disclosure
S. Trudel: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: GlaxoSmithKline. A. Nooka: Honoraria (self), Advisory / Consultancy: Emory University Winship Cancer Institute; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy: Adaptive; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Spectrum; Research grant / Funding (institution): Aduro; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): KITE pharmaceuticals. D. Fecteau: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. M. Talekar: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. R.C. Jewell: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. D. Williams: Full / Part-time employment: GlaxoSmithKline. J. Evans: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. J. Opalinska: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline.
Resources from the same session
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract